U.S., Dec. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07288216) titled 'Transition to KPL-387 Monotherapy Dosing & Administration Study' on Dec. 02.
Brief Summary: The primary objective of this study is to characterize the efficacy and safety of dosing regimens used to transition from prior pericarditis therapies to KPL-387 monotherapy in participants with well-controlled recurrent pericarditis on standard therapies.
Study Start Date: Jan. 31, 2026
Study Type: INTERVENTIONAL
Condition:
Recurrent Pericarditis
Heart Diseases
Pericarditis
Intervention:
DRUG: KPL-387
administered by subcutaneous injection
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Kiniksa Pharmaceuticals International, plc
Pu...